A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications (Crystobs)
Preventing late onset of Cystinosis such as neurological complications and improving compliance to cysteamine treatment remain major challenges in management of subjects with cystinosis.
This study is designed to describe the relationship between compliance of patients with cystinosis treated with cysteamine and treatment efficacy and to understand the pathophysiologic mechanism of neurological disorders. Is cysteamine crossing the blood brain barrier? What is the impact of cystine accumulation in Cerebro Spinal Fluid and Central Nervous System? Our Primary objective is to study the relationship between compliance of patients treated with cysteamine and the WBC cystine level.
Secondary, the study will assess relationship between compliance to cysteamine and its neurological consequences.
The expected duration of the study is 48 months. The enrolment period is 24 months and the study participation of each subject is 24 months. Eligible participants are male and female (age > 4 years) with confirmed diagnosis of cystinosis and receiving any oral cysteamine treatment: Cystagon or RP103.
The compliance under cysteamine is measured using electronic devices, accountability of study treatment, and information in patients' diary. Specific memory and visuoperceptual tests are performed at the beginning and at the end of patients'participation. Nuclear Magnetic Resonance spectroscopy is used to detect possible sites of cystine accumulation in the CNS and their relationship with compliance to cysteamine treatment. NMRS is also used to establish a relationship with the neuropsychological status of the subject.
To describe absorption, distribution and elimination of cysteamine, and its metabolic pathways, and to determine the concentration effect and dose effect relationship, blood samples are performed at each study visit. A lumbar puncture is also proposed to participants to verify if cysteamine is crossing the blood brain barrier. New tools are used to compare metabonomic networks in patients with cystinosis and their controls.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications|
- WBC cystine levels [ Time Frame: Day1and every three months : Month1, Month3, Month6, Month9, Month12, Month15, Month18, Month21 and Month24. ] [ Designated as safety issue: No ]
PD measurements will be performed at D1, M1, M3, M6, M9, M12, M15, M18, M21 and M24.
Compliance under cysteamine will be measured from D1 to M24 using electronic devices (date and time of bottle opening are recorded), accountability of study treatment and information of patients' diary. Compliance measurement between two consecutive study visits will be expressed as the proportion of the observed number of opening compared to the expected number and the cumulated dose taken compared to the expected dose.Compliance will be first considered as a dichotomous variable, the compliance being described as satisfactory if greater than 95% during a specific period.Compliance will then be considered as a quantitative variable
- Presence or absence and accountability of cystine crystals. [ Time Frame: Every 6 month : Month1, Month6, Month12, Month18, Month24 ] [ Designated as safety issue: No ]Eye examination
- Memory and visuoperceptual tests repeated during the study [ Time Frame: at Day 1 and two years ] [ Designated as safety issue: No ]
- presence or absence of cystine accumulation, determination of the sites of cystine accumulation in the CNS and relationship with the compliance to cysteamine treatment, relationship with neuropsychological status. [ Time Frame: at Month 1 and two years ] [ Designated as safety issue: No ]NMRS assessments
- Concentration of cysteamine in the CSF, associated to a measurement of the CSF pressure [ Time Frame: at any visit ] [ Designated as safety issue: No ]
- concentration of cysteamine in blood (measured by toxicological HPLC analysis with fluorescence detection) [ Time Frame: at Day1 and every 3 months : month1, month3, month6, month9, month12, month15, month18, month21, month24 ] [ Designated as safety issue: No ]
- discrimination of urine and blood samples,from metabolic spectroscopic data obtained by nuclear magnetic resonance. [ Time Frame: Every 3 months during 6 months and every 6 months to month 6 until two years ] [ Designated as safety issue: No ]Perturbed metabolic network resulting from the intake of cysteamine in comparison to controls,using urine and blood samples available for patients with cystinosis and their controls
- Concentration effect, dose effect model. [ Time Frame: at month 6 ] [ Designated as safety issue: No ]pharmacokinetic profile and 2 timepoints pharmacodynamics.
|Study Start Date:||December 2011|
|Estimated Study Completion Date:||May 2015|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
No Intervention: Cysteamine Bitartrate
Single arm study. Subjects receive their current oral form of cysteamine bitartrate treatment : Cystagon® or RP103
Other: Cysteamine bitartrate
Please refer to this study by its ClinicalTrials.gov identifier: NCT02012114
|Contact: Pierre COCHAT, PU PH||04 27 85 61 firstname.lastname@example.org|
|Contact: Segolene GAILLARD||04 27 85 77 email@example.com|
|Hospices Civils de Lyon||Recruiting|
|Lyon, France, 69002|
|Study Director:||Cochat Pierre, PUPH||Hospices Civils de Lyon|